Serum Institute of India

Serum Institute of India (SII) is an Indian biotechnology and biopharmaceutical company headquartered in Pune, Maharashtra. Founded in 1966 by Cyrus Poonawalla, the company was established to manufacture immunobiological products that India had previously imported at high prices. It developed a business model centered on high-volume production, broad public-health access, and supply to national and international immunization programs. The company’s early products included tetanus antitoxin, snake antivenom, diphtheria-tetanus-pertussis vaccines, and measles-mumps-rubella vaccines. Over time, its portfolio expanded to include vaccines against bacterial and viral diseases, combination vaccines, influenza vaccines, meningococcal vaccines, tuberculosis and polio vaccines, antisera, blood-plasma products, and selected hormone products. Its vaccines have been used in programs supported by organizations including the World Health Organization, UNICEF, and the Pan American Health Organization. SII operates as part of the Cyrus Poonawalla Group and combines research, product development, technology partnerships, and large-scale manufacturing. Its international expansion included the 2012 acquisition of Bilthoven Biologicals in the Netherlands, its first international acquisition. In 2016, with support from MassBiologics at the University of Massachusetts Medical School, the company announced the development of Rabies Human Monoclonal Antibody, marketed as Rabbishield, intended as a fast-acting treatment component for rabies exposure. The company became especially prominent during the COVID-19 pandemic. It partnered with AstraZeneca and the University of Oxford to manufacture AZD1222, marketed in India and many other markets as Covishield. It also entered manufacturing arrangements for Novavax’s NVX-CoV2373, marketed as Covovax, and for Sputnik V in cooperation with Russia’s Gamaleya Institute. These partnerships positioned SII as a major supplier for India and for lower- and middle-income countries, although production, export restrictions, regulatory reviews, and pandemic supply pressures created operational and political challenges. SII is also a manufacturing partner and developer in malaria vaccine production. Its collaboration with Oxford University and Novavax’s Matrix-M adjuvant technology supported the R21/Matrix-M malaria vaccine, which received a World Health Organization recommendation in 2023. The company reported production capacity of approximately 100 million R21 doses annually, with plans to expand it. By 2023, public reference material described SII as producing roughly 1.9 billion vaccine doses annually, with an ambition to reach approximately 4 billion doses. Its core positioning remains global-scale vaccine manufacturing aimed at making immunization products available at comparatively low cost, especially for childhood immunization and public-health programs.

Serum Institute of India was founded in Pune in 1966 by Cyrus Poonawalla. Its original purpose was to reduce India’s reliance on imported immunobiological products, which were expensive and difficult to obtain at scale. The company began with products such as tetanus antitoxin and snake antivenom, then moved into major childhood and infectious-disease vaccines including DPT and MMR. As its manufacturing capabilities grew, SII expanded into vaccines for bacterial and viral diseases, combination formulations, influenza, meningococcal disease, tuberculosis, and polio. It also developed antisera, plasma-derived products, and hormone products. This portfolio allowed the company to serve both private healthcare channels and large public-health procurement programs. Its products became part of vaccination initiatives associated with the WHO, UNICEF, and PAHO, helping establish the company as an important supplier to international immunization systems. The company’s growth combined internal research and development with external partnerships and manufacturing scale. In 2009 it began development of an intranasal swine flu vaccine. In 2012 it made its first international acquisition, purchasing Bilthoven Biologicals in the Netherlands. In 2016, working with MassBiologics at the University of Massachusetts Medical School, SII developed Rabies Human Monoclonal Antibody, also known as Rabbishield, adding a specialized biologic to its vaccine-centered business. The COVID-19 pandemic brought unprecedented global attention to SII. The company partnered with AstraZeneca and the University of Oxford to manufacture AZD1222, known in India and many other markets as Covishield. SII was expected to supply very large quantities for India and lower- and middle-income countries. It also contracted to manufacture Novavax’s NVX-CoV2373, marketed as Covovax, and reached arrangements concerning Sputnik V production with the Gamaleya Institute and the Russian Direct Investment Fund. Regulatory pauses, changing export policies, supply constraints, and the enormous demand for COVID-19 vaccines made this period operationally and politically complex. SII continued to develop its role in global vaccine supply after the acute phase of the pandemic. Its collaboration with Oxford University and Novavax technology supported the R21/Matrix-M malaria vaccine. In October 2023, the WHO recommended the vaccine for use, and SII reported annual production capacity of around 100 million doses with plans to expand. Public descriptions in 2023 characterized the company as the world’s largest vaccine producer by volume, with output of approximately 1.9 billion doses annually and an ambition to reach 4 billion doses. Its history reflects the development of an Indian manufacturer into a globally significant biotechnology company focused on affordable, high-volume immunization products.

1. 2023WHO recommendation for R21/Matrix-M

   WHO recommends the Oxford-SII malaria vaccine R21/Matrix-M for use.

   Source
2. 2021Sputnik V production plan

   SII announces plans to produce Sputnik V in India under an arrangement involving the Gamaleya Institute and RDIF.

   Source
3. 2020Covishield manufacturing partnership

   SII begins large-scale manufacturing arrangements for the Oxford-AstraZeneca COVID-19 vaccine.

   Source
4. 2016Rabbishield development

   SII and MassBiologics announce development of a human monoclonal antibody for rabies exposure.

   Source
5. 2012Bilthoven Biologicals acquisition

   The company completes its first international acquisition by acquiring Dutch biopharmaceutical company Bilthoven Biologicals.

   Source
6. 2009Intranasal swine flu vaccine development begins

   SII begins developing an intranasal vaccine candidate for swine flu.

   Source
7. 1966Serum Institute of India is founded

   Cyrus Poonawalla establishes SII in Pune to produce immunobiological products previously imported into India.

   Source

A high-volume, cost-conscious vaccine manufacturer serving domestic and international public-health programs through proprietary products and technology partnerships.

• TubervacTuberculosis vaccine

  Tubervac is SII’s BCG tuberculosis vaccine product. It represents the company’s longstanding participation in routine childhood and infectious-disease immunization programs.

• PoliovacPolio vaccine

  Poliovac is a polio vaccination product associated with SII’s supply of vaccines for national and international childhood immunization programs.

• Measles-mumps-rubella vaccineCombination vaccine

  SII produces MMR vaccines used to protect against measles, mumps, and rubella. MMR was among the company’s early large-scale vaccine product lines.

• CovishieldCOVID-19 vaccine2021

  Covishield is the India-market and widely used international name for SII-manufactured doses of the Oxford-AstraZeneca adenoviral-vector COVID-19 vaccine, AZD1222. It became one of SII’s most prominent products during the pandemic.

• CovovaxCOVID-19 vaccine2021

  Covovax is SII’s version of Novavax’s NVX-CoV2373 protein-based COVID-19 vaccine, produced under an arrangement for India and other low- and middle-income countries.

• R21/Matrix-MMalaria vaccine2023

  R21/Matrix-M is a malaria vaccine jointly developed by Oxford University and SII, using Novavax’s Matrix-M adjuvant technology. WHO recommended it in 2023, and SII established substantial manufacturing capacity for the product.

• RabbishieldRabies monoclonal antibody2016

  Rabbishield is the commercial name associated with SII’s Rabies Human Monoclonal Antibody, developed with MassBiologics as a fast-acting anti-rabies biologic.

• 2023Scale production of R21/Matrix-M malaria vaccineProduct launch

  The Oxford-SII malaria vaccine received a WHO recommendation following clinical development and regulatory evaluation.

  What changed. SII established capacity to produce approximately 100 million doses annually and announced plans to increase that capacity.

  Aftermath. R21/Matrix-M broadened SII’s public-health portfolio beyond routine childhood and COVID-19 vaccines.

  Source
• 2021Plan Sputnik V production in IndiaProduct launch

  India sought additional COVID-19 vaccine manufacturing capacity during the pandemic.

  What changed. SII agreed to produce Sputnik V in cooperation with the Gamaleya Institute and the Russian Direct Investment Fund.

  Aftermath. The parties announced an intended production capacity of more than 300 million doses annually.

  Source
• 2020Manufacture Covishield for India and global marketsProduct launch

  The COVID-19 pandemic created urgent demand for a scalable vaccine supply for India and lower- and middle-income countries.

  What changed. SII partnered with AstraZeneca and Oxford University to manufacture AZD1222, marketed as Covishield.

  Aftermath. Covishield became a central part of India’s COVID-19 vaccination effort and SII’s international profile.

  Reported target price per dose. Approximately ₹225 per dose (2020)

  Source
• 2020Add Novavax vaccine manufacturingProduct launch

  SII expanded its COVID-19 manufacturing portfolio beyond the Oxford-AstraZeneca vaccine.

  What changed. The company agreed to manufacture Novavax’s NVX-CoV2373, marketed as Covovax in India.

  Aftermath. The agreement diversified SII’s pandemic vaccine supply and technology partnerships.

  Source
• 2012Acquire Bilthoven BiologicalsM&A

  SII sought international expansion and additional biopharmaceutical manufacturing capabilities.

  What changed. The company acquired Bilthoven Biologicals in the Netherlands, its first international acquisition.

  Aftermath. The transaction expanded SII’s international operating footprint and product-manufacturing capabilities.

  Source

• 2023WHO recommends R21/Matrix-M malaria vaccine

  The World Health Organization’s Strategic Advisory Group of Experts and Malaria Policy Advisory Group recommended use of the R21/Matrix-M malaria vaccine.

  RegulationProduct launch
  Source
• 2021Serum Institute announces Sputnik V production plans

  The Russian Direct Investment Fund announced that SII would begin producing Sputnik V in India, with planned annual output exceeding 300 million doses.

  Product launch
  Source
• 2021Cyber-espionage group targets Serum Institute intellectual property

  Reuters reported that the Chinese state-backed cyber-espionage group Red Apollo targeted SII in an alleged effort to obtain intellectual property and other sensitive information.

  Other
  Source
• 2021Covishield supply agreement with the United Kingdom

  SII reached an agreement to supply some Covishield doses to the United Kingdom during the global COVID-19 vaccine rollout.

  Other
  Source
• 2020Oxford-AstraZeneca COVID-19 vaccine partnership expands

  SII partnered with AstraZeneca and Oxford University to manufacture AZD1222, marketed as Covishield, for India and other countries.

  Product launchOther
  Source
• 2020Indian regulator temporarily halts Oxford vaccine trials

  Clinical-trial activity associated with the Oxford-AstraZeneca vaccine was paused after illness in an Oxford trial participant and later resumed following regulatory review in the United Kingdom.

  RegulationOther
  Source
• 2020Serum Institute seeks emergency authorization for Covishield

  SII sought Indian emergency authorization for the Oxford-AstraZeneca vaccine, which received approval in January 2021.

  RegulationProduct launch
  Source
• 2020Serum Institute agrees to manufacture Novavax vaccine

  The company entered an agreement to produce Novavax’s NVX-CoV2373 vaccine, marketed in India as Covovax, for India and other low- and middle-income markets.

  Product launch
  Source
• 2016Rabies Human Monoclonal Antibody development announced

  With support from MassBiologics, SII developed a fast-acting anti-rabies agent known as Rabies Human Monoclonal Antibody or Rabbishield.

  Product launch
  Source
• 2012Serum Institute acquires Bilthoven Biologicals

  SII completed its first international acquisition by purchasing Bilthoven Biologicals, a Dutch biopharmaceutical company.

  M&A
  Source
• 2009Serum Institute begins development of an intranasal swine flu vaccine

  The company began work on an intranasal vaccine candidate for swine flu, broadening its development activity beyond established routine immunization products.

  Product launch
  Source

1. Serum Institute of India
2. Serum Institute of India official website
3. 网络间谍组织针对印度血清研究所知识产权